The Winter 2020 edition of the newsletter on SWOG's Lung-MAP precision medicine trial is out. Lung-MAP is NCI's first precision trial, and tests new treatments for non-small cell cancer in partnership with the National Cancer Institute, Foundation for the National Institutes of Health, and Friends of Cancer Research.

The newsletter gives a grateful accounting of progress made during this remarkable year, with over 900 study registrations. It also also includes links to the latest Lung-MAP manuscript, published in The Lancet Oncology, and a list of new study leaders. Read the newsletter here.

Other Recent Stories

SWOG Front Line banner
Aug 21, 2026
Turning AI to finding clinical trials for patients
Federal and Industry Sponsorship in US Cancer Clinical Trials
Aug 20, 2026
New research details the vital, unique role federal support plays in cancer clinical research
SWOG Front Line banner
Aug 14, 2026
Three studies from our NCORP RB have reported primary results recently